It is believed that Johnson & Johnson, which owns DePuy Orthopaedics, will sell the trauma business to help satisfy regulatory concerns relating to its $21.3 billion agreement to acquire Synthes announced last year, according to numerous news reports. Regulators have expressed concern that the acquisition of Synthes would give DePuy close to a monopoly on the trauma business.
Biomet’s offer expires June 1, but can be extended.
“This transaction will provide Biomet with a much stronger presence in the global trauma market and greatly expands our sports, extremities and trauma business, which is a meaningful growth driver for Biomet,” said Jeffrey R. Binder, president and CEO of Biomet, in the release. “The DePuy trauma team has done a great job of building a successful business. We look forward to welcoming them as Biomet team members and working alongside them to fulfill our commitment to providing customers with outstanding products and service, as well as continued innovation.”
Related Articles on Company Acquisitions:
RadNet Acquires West Coast Radiology
Ventas Completes Acquisition of Cogdell Spencer
Express Scripts Completes Acquisition of Medco
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
